The oncogenic phenotype of activated KRAS is followed by loss of phosphatase and tensin homolog (PTEN), which is a tumor suppressor gene that inhibits the PI3K/AKT signaling pathway and has a prevalence of 60% in PDAC (Figure 5D) [103]. This evidence concerns the gene PTEN and neoplasm.